0001171843-20-005681.txt : 20200806 0001171843-20-005681.hdr.sgml : 20200806 20200806165709 ACCESSION NUMBER: 0001171843-20-005681 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20200806 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20200806 DATE AS OF CHANGE: 20200806 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Molecular Templates, Inc. CENTRAL INDEX KEY: 0001183765 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 943409596 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-32979 FILM NUMBER: 201082510 BUSINESS ADDRESS: STREET 1: 9301 AMBERGLEN BLVD STREET 2: SUITE 100 CITY: AUSTIN STATE: TX ZIP: 78729 BUSINESS PHONE: 512 896 1555 MAIL ADDRESS: STREET 1: 9301 AMBERGLEN BLVD STREET 2: SUITE 100 CITY: AUSTIN STATE: TX ZIP: 78729 FORMER COMPANY: FORMER CONFORMED NAME: THRESHOLD PHARMACEUTICALS INC DATE OF NAME CHANGE: 20020828 8-K 1 f8k_080620.htm FORM 8-K Form 8-K
0001183765 False 0001183765 2020-08-06 2020-08-06 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_________________

FORM 8-K

_________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  August 6, 2020

_______________________________

Molecular Templates, Inc.

(Exact name of registrant as specified in its charter)

_______________________________

Delaware001-3297994-3409596
(State or Other Jurisdiction of Incorporation)(Commission File Number)(I.R.S. Employer Identification No.)

9301 Amberglen Blvd, Suite 100

Austin, Texas 78729

(Address of Principal Executive Offices) (Zip Code)

(512) 869-1555

(Registrant's telephone number, including area code)

 

(Former name or former address, if changed since last report)

_______________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, $0.001 Par Value Per ShareMTEMThe Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 
 
Item 2.02. Results of Operations and Financial Condition.

On August 6, 2020, Molecular Templates, Inc. (the "Company") announced its financial results for the second quarter of 2020 ended June 30, 2020. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information contained in this Item 2.02 and in the press release furnished as Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 2.02 and in the press release furnished as Exhibit 99.1 to this current report on Form 8-K shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Item 9.01. Financial Statements and Exhibits.
   
Exhibit 99.1 Press Release dated August 6, 2020
Exhibit 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
 
 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 Molecular Templates, Inc.
   
  
Date: August 6, 2020By: /s/ Eric E. Poma, Ph.D.        
  Eric E. Poma, Ph.D.
  Chief Executive Officer
  

 

 EX-99.1 2 exh_991.htm PRESS RELEASE EdgarFiling

EXHIBIT 99.1

Molecular Templates, Inc. Reports Second Quarter 2020 Financial Results

AUSTIN, Texas, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” “MTEM” or “the Company”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), today reported financial results for the second quarter of 2020.

“Since our last quarterly update, we presented preclinical data at AACR on four preclinical ETB programs, provided an update on the ongoing Phase I study for MT-5111, and strengthened our balance sheet through a new debt facility and our ATM,” said Eric Poma, Ph.D., Molecular Templates’ Chief Executive and Chief Scientific Officer. “In the second half of 2020, we expect to report interim clinical data from our three MT-3724 Phase 2 studies and additional data from the MT-5111 Phase 1 study, and also file the IND for MT-6402, our PD-L1-targeted ETB with antigen seeding.”

Company Highlights, Pipeline Status, and Upcoming Milestones

Corporate

  • On May 22, 2020, MTEM announced it had secured a debt financing facility for up to $45 million from K2 HealthVentures, a healthcare-focused specialty finance company. MTEM received a first tranche of $15 million upon closing. Two subsequent tranches totaling $30 million will become available upon the achievement of certain milestones.
  • In July 2020, MTEM raised $50 million in gross proceeds from its At-The-Market Facility (ATM).

MT-3724 (CD20 ETB)

  • MTEM is currently conducting three Phase 2 studies with MT-3724 in relapsed/refractory diffuse large B-cell lymphoma (DLBCL): a monotherapy study that has the potential to be pivotal, a combination study with chemotherapy, and a combination study with lenalidomide.
  • Interim results for the study of MT-3724 in combination with lenalidomide were presented at the 25th Congress of the European Hematology Association (EHA) virtual meeting in June 2020.  This data demonstrated preliminary evidence of tolerability and efficacy with lenalidomide at standard doses and MT-3724. Among 7 evaluable subjects, 2 had CRs and 3 had PRs. While there were no permanent discontinuations due to adverse events, grade 2 capillary leak syndrome occurred at 25 mcg/kg, leading to the opening of a new cohort at 20 mcg/kg. The study now has a new schedule of therapy with MT-3724 being dosed twice rather than three times weekly for the first two cycles, and then on a weekly schedule thereafter.
  • MTEM expects to report updates on all three MT-3724 DLBCL studies in 2H20.
  • MTEM also expects to initiate Phase 2 studies for MT-3724 in follicular lymphoma and mantle cell lymphoma in 2H20.   

TAK-169 (CD38 ETB)

  • Takeda and MTEM are conducting an ongoing Phase 1 study evaluating TAK-169 in relapsed/refractory multiple myeloma.

MT-5111 (HER2 ETB)

  • MTEM is conducting a Phase 1 study of MT-5111 in HER2-positive cancers.
  • In June 2020, MTEM provided an interim update from the first three dose cohorts of the dose escalation portion of the Phase 1 study. That update noted that 10 subjects, with a median of 5 prior lines of therapy and a median of 2 prior HER2-targeting regimens, have been treated with MT-5111 (metastatic cholangiocarcinoma n=5, metastatic breast cancer n=4, metastatic gastro-esophageal junction carcinoma n=1).  Thus far, no dose limiting toxicities (DLTs) have been observed in any cohort and MT-5111 appears to be well tolerated, with no cardiotoxicity observed to date (cardiotoxicity is a known potential toxicity for HER2 targeted therapies).
  • Further to the June 2020 interim update, MTEM expects to provide an update on results from the subjects still on treatment as well as higher dose cohorts from the dose escalation portion of the Phase 1 study (including doses that are predicted to be clinically active based on preclinical data) in 4Q20.

Research

  • MTEM presented preclinical data on ETB programs targeting PD-L1, CTLA-4, SLAMF-7 and CD45 at the American Association for Cancer Research (AACR) Virtual Annual Meeting II, which took place June 22-24, 2020.
  • MTEM expects to file an investigational new drug (IND) application for MT-6402, its ETB targeting PD-L1 (with antigen seeding), in 2H20.
  • MTEM expects to file an IND application for its ETB targeting CTLA-4 in 2021.

COVID-19 Impact

  • The COVID-19 pandemic has resulted in a significant slowdown in the pace of site initiations and patient enrollment across our MT-3724 Phase 2 programs. Much like other sponsors with studies in patients with hematologic malignancies, we are working with sites to determine when a patient is suitable for each research study and to ensure the continued safety of all research participants.  
  • To date, screening and enrollment for the MT-5111 Phase 1 study has been less adversely affected than the MT-3724 studies but it is enrolling at slower pace than was projected pre-COVID-19.
  • To date, MTEM has been able to continue to work at its cGMP manufacturing facility and laboratories without interruption from COVID-19. As a result, manufacturing of product supply for clinical trials and research activities to support advancement of our preclinical pipeline (including partnered programs) have not been adversely affected by COVID-19 to date.

Financial Results

The net loss attributable to common shareholders for the second quarter of 2020 was $31.2 million, or $0.68 per basic and diluted share. This compares with a net loss attributable to common shareholders of $9.2 million, or $0.25 per basic and diluted share, for the same period in 2019.

Revenues for the second quarter of 2020 were $6.9 million, compared to $5.4 million for the same period in 2019. Revenues for the second quarter of 2020 were comprised of revenues from collaborative research and development agreements with Takeda and Vertex, as well as grant revenue from CPRIT. Total research and development expenses for the second quarter of 2020 were $30.4 million, compared with $10.2 million for the same period in 2019. Total general and administrative expenses for the second quarter of 2020 were $6.4 million, compared with $4.6 million for the same period in 2019.

As of June 30, 2020, MTEM’s cash and investments totaled $91.0 million. With the addition of $50 million in gross proceeds raised through MTEM’s ATM facility after the end of the quarter, MTEM expects to be able to fund operations into 2H22.

About Molecular Templates

Molecular Templates is a clinical-stage company focused on the discovery and development of targeted biologic therapeutics. Our proprietary drug platform technology, known as engineered toxin bodies, or ETBs, leverages the resident biology of a genetically engineered form of Shiga-like Toxin A subunit to create novel therapies with potent and differentiated mechanisms of action for cancer and other serious diseases.

Forward-Looking Statements

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the “Act”). Molecular Templates disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Act’s Safe Harbor for forward-looking statements.  All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial position, future revenue, projected expenses, prospects, plans and objectives of management are forward-looking statements. In addition, when or if used in this press release, the words “may,” “could,” “should,” “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “predict” and similar expressions and their variants, as they relate to Molecular Templates may identify forward-looking statements.  Examples of such statements include, but are not limited to, statements relating to the development of the MT-3724, MT-5111, TAK-169, and MT-6402; the expected timing of submitting various IND applications and conducting studies; the expected participation and presentation at upcoming medical conferences; the anticipated effects of the COVID-19 pandemic on the Company’s ongoing clinical studies, manufacturing and preclinical development; and the Company’s belief that its proprietary biologic drug platform technology, or ETBs, provides for a differentiated mechanism of action that may address some of the limitations associated with currently available cancer therapeutics.

Forward-looking statements are not guarantees of future performance and involve risks and uncertainties. Actual events or results may differ materially from those discussed in the forward-looking statements as a result of various factors including, but not limited to, the uncertainties inherent in the preclinical and clinical development process; whether the Company’s cash resources will be sufficient to fund its continuing operations for the periods and/or trials anticipated; the ability of the Company to protect its intellectual property rights; risks from global pandemics including COVID-19; and legislative, regulatory, political and economic developments, as well as those risks identified under the heading “Risk Factors” in the Company’s filings with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and the Company specifically disclaims any obligation to update any forward-looking statement, whether because of new information, future events or otherwise.

Contact:

Adam Cutler
Chief Financial Officer
adam.cutler@mtem.com
862-204-4006



Molecular Templates, Inc.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except share and per share data)
(unaudited)

 Three Months Ended
June 30,		 Six Months Ended
June 30,		 
 2020  2019 2020  2019 
Research and development revenue, related party$3,063  $5,211 $3,396  $11,624 
Research and development revenue, other 2,977   —  4,444   — 
Grant revenue 869   236  3,210   831 
Total revenue 6,909   5,447  11,050   12,455 
Operating expenses:              
Research and development 30,414   10,243  51,045   18,697 
General and administrative 6,412   4,605  12,059   9,540 
Total operating expenses 36,826   14,848  63,104   28,237 
Loss from operations 29,917   9,401  52,054   15,782 
Interest and other income, net 286   543  758   1,053 
Interest and other expense, net (360)  (301) (708)  (594)
Loss on extinguishment of debt (1,237)  —  (1,237)  — 
Change in fair value of warrant liabilities —   6  —   2 
Loss before provision for income taxes 31,228   9,153  53,241   15,321 
Provision for income taxes —   —  5   — 
Net loss 31,228   9,153  53,246   15,321 
Net loss attributable to common shareholders$31,228  $9,153 $53,246  $15,321 
Net loss per share attributable to common shareholders:              
Basic and diluted$0.68  $0.25 $1.17  $0.42 
Weighted average number of shares used in net loss per share calculations: 45,725,481   36,819,846  45,687,278   36,779,638 
Basic and diluted              


Molecular Templates, Inc.
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands, except share and per share data)

 June 30,
2020 (unaudited)		  December 31,
2019		 
ASSETS       
Current assets:       
Cash and cash equivalents$27,645  $85,451 
Marketable securities, current 63,361   39,633 
Prepaid expenses 3,347   2,318 
Grants revenue receivable 5,900   7,100 
Accounts receivable, related party 3,167   408 
In-process research and development - held for sale 4,500   4,500 
Other current assets 160   489 
Total current assets 108,080   139,899 
Marketable securities, non-current —   1,510 
Operating lease right-of-use assets, non-current 9,266   9,959 
Property and equipment, net 20,224   18,158 
Other assets 4,840   4,676 
Total assets$142,410  $174,202 
LIABILITIES AND STOCKHOLDERS’ EQUITY       
Current liabilities:       
Accounts payable$1,660  $1,465 
Accrued liabilities 14,129   14,544 
Deferred revenue, current 13,284   8,511 
Deferred revenue, current, related party 5,218   8,780 
Other current liabilities, related party 5,325   — 
Other current liabilities 1,785   2,501 
Total current liabilities 41,401   35,801 
Deferred revenue, long-term 9,728   18,944 
Deferred revenue, long-term, related party 1,849   441 
Long-term debt, net 14,721   2,940 
Operating lease liabilities, non-current 10,771   11,682 
Other liabilities, related party 6,654   — 
Other liabilities 1,427   1,366 
Total liabilities 86,551   71,174 
Commitments and contingencies (Note 10)       
Stockholders’ equity       
Preferred stock, $0.001 par value:       
Authorized: 2,000,000 shares at June 30, 2020 and December 31, 2019; issued and
  outstanding: 250 shares at June 30, 2020 and December 31, 2019		 —   — 
Common stock, $0.001 par value:       
Authorized: 150,000,000 shares; issued and outstanding: 45,778,876 shares at
  June 30, 2020 and 45,589,157 shares at December 31, 2019		 46   46 
Additional paid-in capital 273,012   267,089 
Accumulated other comprehensive income 172   18 
Accumulated deficit (217,371)  (164,125)
Total stockholders’ equity 55,859   103,028 
Total liabilities and stockholders’ equity$142,410  $174,202 

 EX-101.SCH 3 gnw-20190101.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 4 gnw-20190101_def.xml XBRL DEFINITION FILE EX-101.LAB 5 gnw-20190101_lab.xml XBRL LABEL FILE Class of Stock [Axis] Common Class A [Member] Preferred Class A [Member] Statement [Table] Statement [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 gnw-20190101_pre.xml XBRL PRESENTATION FILE XML 7 f8k_080620_htm.xml IDEA: XBRL DOCUMENT 0001183765 2020-08-06 2020-08-06 iso4217:USD shares iso4217:USD shares 0001183765 false 8-K 2020-08-06 Molecular Templates, Inc. DE 001-32979 94-3409596 9301 Amberglen Blvd, Suite 100 Austin TX 78729 512 869-1555 false false false false Common Stock, $0.001 Par Value Per Share MTEM NASDAQ false XML 8 R1.htm IDEA: XBRL DOCUMENT v3.20.2
Cover
Aug. 06, 2020
Document Type 8-K
Amendment Flag false
Document Period End Date Aug. 06, 2020
Entity File Number 001-32979
Entity Registrant Name Molecular Templates, Inc.
Entity Central Index Key 0001183765
Entity Tax Identification Number 94-3409596
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 9301 Amberglen Blvd, Suite 100
Entity Address, City or Town Austin
Entity Address, State or Province TX
Entity Address, Postal Zip Code 78729
City Area Code 512
Local Phone Number 869-1555
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.001 Par Value Per Share
Trading Symbol MTEM
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.2 html 1 95 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://globenewswire.com/role/Cover Cover Cover 1 false false All Reports Book All Reports f8k_080620.htm exh_991.htm gnw-20190101.xsd gnw-20190101_def.xml gnw-20190101_lab.xml gnw-20190101_pre.xml http://xbrl.sec.gov/dei/2019-01-31 http://fasb.org/us-gaap/2019-01-31 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "f8k_080620.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "local": [ "gnw-20190101_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml" ] }, "inline": { "local": [ "f8k_080620.htm" ] }, "labelLink": { "local": [ "gnw-20190101_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "gnw-20190101_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "gnw-20190101.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd", "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 63, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 0, "memberStandard": 0, "nsprefix": "gnw", "nsuri": "http://globenewswire.com/20190101", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "f8k_080620.htm", "contextRef": "Form8K", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://globenewswire.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "f8k_080620.htm", "contextRef": "Form8K", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r10" ], "lang": { "en-US": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r13" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The start date of the period covered in the document, in CCYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r9" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r10" ], "lang": { "en-US": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r10" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r12" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r18" ], "lang": { "en-US": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r10" ], "lang": { "en-US": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r7" ], "lang": { "en-US": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r8" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r17" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_CommonClassAMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Common Class A [Member]" } } }, "localname": "CommonClassAMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredClassAMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Preferred Class A [Member]" } } }, "localname": "PreferredClassAMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "stringItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r10": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r11": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r12": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1-" }, "r13": { "Name": "Forms 10-K, 20-F, 40-F", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d-1" }, "r14": { "Name": "Forms 20-F, 40-F", "Number": "249", "Publisher": "SEC", "Section": "220 and 240", "Subsection": "f" }, "r15": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r18": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r9": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-13" } }, "version": "2.1" } ZIP 15 0001171843-20-005681-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001171843-20-005681-xbrl.zip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